Summary
Harvard Medical School researchers modeled a simple question. What happens if German drug prices rise by 25 percent? The study, published November 11, 2026, was commissioned by GKV-Spitzenverband, Germany’s national association of statutory health insurers. The insurers say the Harvard team kept full control over the methods and findings. Consequently, the result cuts against the funder’s own policy preference: both countries would pay more, not less.
Access Impact
Higher German prices do not stay in Germany.
The study found a 25 percent German price increase would add about $6.2 billion to German insurer spending and roughly $300 million to US Medicaid spending. The US exposure exists because of most-favored-nation (MFN) pricing, which sets domestic benchmarks using prices observed abroad. Germany carries particular weight in these benchmarks. Specifically, new medicines tend to launch there earlier than in most other reference markets, so German list prices often set the early tone for US calculations. As a result, a German pricing decision made for domestic reasons can move a US budget line it was never designed to touch. This is why the mechanism deserves scrutiny as a market access risk, not just a trade or diplomacy story. Three scoring domains explain why.
Comparator Selection
Most-favored-nation pricing is, at its core, a comparator selection exercise. It picks a basket of foreign prices and treats that basket as a stable external benchmark for US policy. However, the benchmark is only as stable as the countries inside it. Germany passed a reform in July 2026 that raised mandatory manufacturer rebates. The US Trade Representative opened a Section 301 investigation into German pricing practices the prior month. Both actions show the comparator moving in real time. A rating framework that treats comparator countries as fixed inputs will systematically understate this risk.
Budget Impact
The $300 million Medicaid figure is small next to total US drug spending, but it is a sharp signal. It shows that budget impact models tied to foreign reference prices inherit foreign volatility by construction. Germany’s insurers argue, not without self-interest, that higher German prices would not actually lower US prices, since manufacturers would be the main beneficiaries of increased spending on both sides. Independent of which side is right, the dispute itself confirms that MFN-linked budget projections carry assumptions that have not been stress-tested against each country’s own policy response. That is a defensible point of scrutiny for any reimbursement model built on cross-border pricing.
Evidence Quality
The study’s funding source matters to how the evidence should be weighted. GKV-Spitzenverband has a direct financial interest in resisting pressure to raise German prices, and it paid for this analysis. The insurers’ disclosure that Harvard retained full control over design and conclusions is a standard step toward credibility, but it does not substitute for independent replication. Readers assessing this evidence should therefore treat the direction of the finding as informative while treating the precise dollar figures as provisional. Notably, the finding that both countries lose runs against the funder’s commercial interest, which somewhat strengthens its credibility on that specific point.
Risk Signal
A policy anchored elsewhere still lands at home.
This episode is a reminder that cross-border reference pricing does not eliminate market access risk. It relocates that risk, and sometimes amplifies it, by tying one country’s budget outcomes to another country’s domestic politics. Eli Lilly, Boehringer Ingelheim, and Pfizer have already signaled reduced German investment in response to pricing pressure, and Roche paused its German expansion in October 2026. For portfolio managers and acquirers, this raises a pointed question: how many current pricing and reimbursement assumptions rest on a foreign benchmark that could shift before the asset reaches peak sales?
#MarketAccess #HTA #MARArating #DrugPricing #Medicaid
Explore independent market access assessments: https://mararating.com/market-access-pharma/
Explore the full MARA ratings list: https://mararating.com/mara-ratings-list